Avadel Pharmaceuticals (NASDAQ:AVDL) & Nuvilex (NASDAQ:PMCB) Financial Analysis

Nuvilex (NASDAQ:PMCB) and Avadel Pharmaceuticals (NASDAQ:AVDL) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk.

Profitability

This table compares Nuvilex and Avadel Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nuvilex	N/A	-6.41%	-5.77%
Avadel Pharmaceuticals	-0.11%	-0.33%	-0.15%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Nuvilex and Avadel Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvilex	1	0	0	0	1.00
Avadel Pharmaceuticals	2	10	1	0	1.92

Avadel Pharmaceuticals has a consensus price target of $18.13, suggesting a potential downside of 15.07%. Given Avadel Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Avadel Pharmaceuticals is more favorable than Nuvilex.

Earnings & Valuation

This table compares Nuvilex and Avadel Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvilex	N/A	N/A	$30.66 million	($0.54)	-2.26
Avadel Pharmaceuticals	$169.12 million	12.32	-$48.83 million	N/A	N/A

Nuvilex has higher earnings, but lower revenue than Avadel Pharmaceuticals.

Insider and Institutional Ownership

34.2% of Nuvilex shares are held by institutional investors. Comparatively, 69.2% of Avadel Pharmaceuticals shares are held by institutional investors. 10.3% of Nuvilex shares are held by insiders. Comparatively, 5.2% of Avadel Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

Nuvilex has a beta of 0.06, suggesting that its stock price is 94% less volatile than the S&P 500. Comparatively, Avadel Pharmaceuticals has a beta of 1.26, suggesting that its stock price is 26% more volatile than the S&P 500.

Summary

Avadel Pharmaceuticals beats Nuvilex on 8 of the 11 factors compared between the two stocks.

About Nuvilex

PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

About Avadel Pharmaceuticals

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.